-
<![CDATA[Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress]]>
13 Oct 2025 22:45 GMT
… plus fluorouracil, leucovorin, oxaliplatin, and docetaxel in patients with resectable gastric … EGFR-mutated non–small cell lung cancer (NSCLC).
____
That’s all …
-
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
13 Oct 2025 13:40 GMT
… metastatic non-small cell lung cancer (mNSCLC): VELOCITY-Lung … docetaxel in patients (Pts) with metastatic non-small cell lung cancer … ) metastatic non-small cell lung cancer (mNSCLC) Abstract #1885P … 90% of breast and lung cancers. Trodelvy is intentionally …
-
Peritoneal Metastasis in Non-Small Cell Lung Cancer: A Systematic Review of Clinical Features, Molecular Profiles, Diagnostic Approaches, and Outcomes
19 Sep 2025 09:19 GMT
… to metastatic lung cancer complicated with … lung cancer independent of oncogene status. Lung Cancer. … lung cancer with peritoneal carcinomatosis effectively treated with docetaxel. Japanese J Lung Cancer … cell lung cancer by functional class. Lung Cancer. …
-
Japan’s MHLW approves Novocure’s Optune Lua to treat unresectable advanced/recurrent non-small cell lung cancer
16 Sep 2025 11:35 GMT
… /PD-L1 inhibitors or docetaxel alone (control arm) for patients … , assessed Optune Lua concurrently with docetaxel versus docetaxel alone.
Patients randomized to … -small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It …
-
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
15 Sep 2025 11:08 GMT
… Lua concurrently with docetaxel versus docetaxel alone.
Patients … -Small Cell Lung Cancer (NSCLC)
Lung cancer is the most … lung cancer (NSCLC) accounts for approximately 85% of all lung cancers … non-small cell lung cancer, malignant pleural mesothelioma …
-
Kelun-Biotech’s TROP2 ADC Sac-TMT receives China NMPA marketing approval to treat EGFRm NSCLC following progression on EGFR-TKI therapy
13 Oct 2025 07:45 GMT
… current standard of care of docetaxel, sac-TMT monotherapy significantly extends … marking another major milestone in lung cancer treatment. EGFR mutations are the … of lung cancer primarily includes non-small cell lung cancer (NSCLC) and small cell lung cancer …
-
Induction Chemoimmunotherapy Followed by Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
13 Oct 2025 07:14 GMT
… However, the standard TPF (docetaxel, cisplatin, 5-fluorouracil) regimen … In non-small cell lung cancer, combining immunotherapy with chemoradiotherapy … , non-small cell lung cancer has witnessed extensive clinical … III non-small-cell lung cancer. J Clin Oncol. …
-
WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care
12 Sep 2025 22:10 GMT
… 2025 World Conference on Lung Cancer (WCLC), experts from … exhibit updated findings in lung cancer therapy. Presenters and researchers … 6) among those who received docetaxel (n = 30; HR, … completely resected non-small cell lung cancer (NSCLC) patients: first …
-
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC
10 Sep 2025 09:37 GMT
… cadonilimab in IO-resistant lung cancer. The cadonilimab combination … pulocimab for IO-resistant lung cancer. Additionally, ivonescimab (PD … within a year. Docetaxel is the standard therapy … potential in IO-resistant lung cancer, notably extending patient …
-
OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer
08 Sep 2025 12:00 GMT
… compared to docetaxel in squamous non-small cell lung cancer (sqNSCLC) … of the drug beyond lung cancers for other indications … cell lung cancer (NSCLC) Squamous cell non-small cell lung cancer makes … all lung cancers, and is the most common lung cancer found …
About
© 1995-2025